Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
doi: https://doi.org/10.1101/2023.12.04.23297559
Filipa Lynce
1Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA
3Harvard Medical School, Boston, MA, USA
Candace Mainor
4MedStar Georgetown University Hospital, Washington, DC, USA
Renee N. Donahue
5Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Xue Geng
6Georgetown University, Washington, DC
Greg Jones
7NeoGenomics, Research Triangle Park, NC, USA
Ilana Schlam
8MedStar Washington Hospital Center, Washington, DC, USA
9Tufts Medical Center, Boston, MA, USA,
Hongkun Wang
6Georgetown University, Washington, DC
Nicole J. Toney
5Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Caroline Jochems
5Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Jeffrey Schlom
5Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Jay Zeck
4MedStar Georgetown University Hospital, Washington, DC, USA
Christopher Gallagher
8MedStar Washington Hospital Center, Washington, DC, USA
Rita Nanda
10University of Chicago, Chicago, IL, USA
Deena Graham
11Hackensack University Medical Center, Hackensack, NJ, USA
Erica M Stringer-Reasor
12University of Alabama at Birmingham, Birmingham, AL, USA
Neelima Denduluri
13AstraZeneca, Arlington, VA, USA
Julie Collins
4MedStar Georgetown University Hospital, Washington, DC, USA
Ami Chitalia
8MedStar Washington Hospital Center, Washington, DC, USA
Shruti Tiwari
8MedStar Washington Hospital Center, Washington, DC, USA
Raquel Nunes
14Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA;
Rebecca Kaltman
15Inova, Fairfax, VA, USA
Katia Khoury
12University of Alabama at Birmingham, Birmingham, AL, USA
Margaret Gatti-Mays
16The Ohio State University, Columbus, OH, USA
Paolo Tarantino
1Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
3Harvard Medical School, Boston, MA, USA
Sara M. Tolaney
1Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA
3Harvard Medical School, Boston, MA, USA
Sandra M Swain
6Georgetown University, Washington, DC
Paula Pohlmann
4MedStar Georgetown University Hospital, Washington, DC, USA
Heather A. Parsons
1Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA
3Harvard Medical School, Boston, MA, USA
Claudine Isaacs
6Georgetown University, Washington, DC
Posted December 04, 2023.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
medRxiv 2023.12.04.23297559; doi: https://doi.org/10.1101/2023.12.04.23297559
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
medRxiv 2023.12.04.23297559; doi: https://doi.org/10.1101/2023.12.04.23297559
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2661)
- Dermatology (224)
- Emergency Medicine (402)
- Epidemiology (12264)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4122)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2670)
- Health Policy (1008)
- Hematology (364)
- HIV/AIDS (855)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (441)
- Neurology (3912)
- Nursing (210)
- Nutrition (582)
- Oncology (2048)
- Ophthalmology (587)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (455)
- Public and Global Health (6551)
- Radiology and Imaging (1410)
- Respiratory Medicine (872)
- Rheumatology (412)
- Sports Medicine (344)
- Surgery (452)
- Toxicology (54)
- Transplantation (186)
- Urology (167)